Amendment_No._2_-_Questions_and_Responses_Cidofovir.pdf
PDF 103 KB Posted
- Solicitation number
- HHS-ASPR-CSS-75A50119R00042
About this file
AMENDMENT NO. 0002 - QUESTIONS AND RESPONSES.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Amendment-No._0001_75A50119R00042.pdf | ||
| CSS_-_cidofovir_-_HMO_7_17_2019.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Office of the Assistant Secretary for Preparedness and Response (ASPR) Cidofovir (Vistide) injection 375mg/5ml single dose vial NDC 23155-216-31 Solicitation Number: HHS-ASPR-CSS-75A50119R00042
AMENDMENT NO. 2 – QUESTIONS AND RESPONSES
QUESTIONS RESPONSES
Question No. 1
Do I need to submit new pricing information along with the amendment?
Response No. 1
A pricing quote has to be submitted separately from the technical quote and must be clearly identified as the pricing quote. The pricing information does not need to be changed.
However, a separate pricing quote still has to be submitted.
Question No. 2
It stays to submit 2 volumes. Technical Quote and Price Quote. Would the Technical Quote be a submittal of the item’s technical data?
Response No. 2
Yes, we would like to see the technical data of the item that each offeror is informing they will be providing to the requestor. The requestor must ensure that the offeror will be providing the proper pharmaceutical product dosage, strength, size, etc. to meet their mission requirements.
Note: Both Technical and Price quotes are due August 16, 2019 by 5:00pm, EST. Offerors will be considered nonresponsive if quotes are not submitted in two separate volumes.
File details come from the government source that posted it.